Published in Cancer Weekly, June 26th, 2001
Prostate cancer detection is currently based on three diagnostic tests: serum prostate-specific antigen (PSA), digital rectal examination, and transrectal ultrasonography. Widespread use of PSA as a screening tool has led to increased numbers of patients who are evaluated with prostate biopsy; however, conventional systematic biopsy strategies fail to detect about a third of prostate cancers.
Cancerous tissue generally grows more rapidly than healthy tissue...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.